DOCSLIB.ORG

Production of Formaldehyde from N5-Methyltetrahydrofolate by Normal and Leukemic Leukocytes1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Production of Formaldehyde from N5-Methyltetrahydrofolate by Normal and Leukemic Leukocytes1 [CANCER RESEARCH 37, 1125-1132, April 1977) Production of Formaldehyde from N5-Methyltetrahydrofolate by Normal and Leukemic Leukocytes1 Janet Thorndike and William S. Beck Department of Medicine, Harvard Medical School, and Hematology Research Laboratory, Massachusetts General Hospital, Boston, Massachusetts 02114 SUMMARY malian tissues (3, 14, 22, 25, 29, 46). It was first considered that the methyl group was transferred intact in analogy with Extracts of human normal and leukemic leukocytes con the methyl transfer known to take place from AdoMet to tam an enzyme that catalyzes a transfer of labeled methyl various amines (2). This early conclusion rested on the carbon from Ns@[i4C]methyltetnahydrofoIate to tryptamine. assumption that radioactive reaction products were N- Evidence is presented that this reaction is not attributable to methyl derivatives of the amine substrates (14, 22). How a methyltransferase but to the following reaction sequence: even, later studies identified the products as the come (a) an oxidation of N5-[―C]methyltetrahydrofolate to N5,N'°- sponding carbolines formed by spontaneous condensation [i4Clmethylenetetrahydrofolate that is catalyzed by N5,N10- of amines with HCHO (4, 17, 28, 29, 36, 42, 46). These data methylenetetrahydnofolate reductase (EC 1.1.1.68); (b) suggested that transfer of the methyl carbon from CH3- spontaneous release of [“C]fonmaldehydefrom N5,N10- H4folate to an aromatic amine occurs in 2 steps: an enzy [“C]methylenetetrahydrofolate; and (C) nonenzymatic con matic conversion pf CH3-H4folate to HCHO, followed by a densation of [‘4C]formaldehydewith tryptamine to form a nonenzymatic reaction of HCHO with amine. radioactive carboline derivative. The occurrence of this se It was then shown that, in assays for Ns,Nio@methyIene@ quence inleukocytesissuggestedby datathatshow that H4folate reductase (EC 1.1.1.68) by the method of Kutzbach the enzyme reaction is strongly stimulated by addition of and Stokstad (20), tissue extracts catalyze a conversion of flavin adenine dinucleotide and that the final product is CH3-H4folate to HCHO; i.e., CH3-H4folate is oxidized in the chromatognaphically identical to the adduct formed in the presence of an electron acceptor to N5,N'°-methylene reaction of [“C]fonmaldehydewith tryptamine. In the ab H4folate, which then dissociates to HCHO and H4folate (9, sence of tnyptamine, a product accumulates that can react 10, 20). This observation is of interest because transfer of with other HCHO acceptors, i.e., f3-phenylethylamine and the methyl carbon from CH3-H4folateto amines is stimulated dimedone; another reaction product is tetnahydnofolate. by electron acceptors such as FAD on menadione (15, 31, Production of formaldehyde is relatively more active in 44). normal lymphocytes than in normal granulocytes, but it is We have been prompted to study this reaction of CH3- even higher in lymphocytes of chronic lymphocytic leuke H4folate in human hematic tissues because of the particular mia. Activity in granulocytes from a subject with chronic importance of tissue folate metabolism and the controven myelocytic leukemia is also elevated but to a lessen extent sies that have surrounded the distinctive cobalamin-de than activity in lymphocytes of chronic lymphocytic leuke pendent reaction, in which the methyl group of CH3-H4folate mia. Formaldehyde production in leukocytes is only slightly is transferred to homocysteine (28, 39). The purposes of this stimulated by addition of various cobalamins, and activity is study are: (a) to determine whether a transfer of the methyl normal in leukocytes from a vitamin B12-deficient patient. carbon of CH3-H4folateto tryptamine occurs in human Ieu We conclude that the system is cobalamin independent. kocytes; (b) to characterize the nature of this reaction ; (c) to Thus, there exists an active pathway from N5-methyltetrahy compare levels of the reaction in leukocytes from normal drofolate to tetrahydrofolate other than the one catalyzed by individuals and subjects with leukemia and other disorders; cobalamin-dependent N5-methyltetnahydrofolate-homocys and (d) to determine to what extent a cobalamin-independ teinemethyltransfenase. ent conversion of CH3-H4folate to H4folate can occur in these cells. INTRODUCTION Transfer of the methyl carbon from CH3-H4folate2to ano MATERIALS AND METHODS matic amines has been demonstrated in a variety of mam Reagents. [‘4C]CH3-H4folate(54@Ci/@tmoIe),[2-'4C]folic I This work was supported by Research Grant CA-03728 from the National acid (58 @Ci/@moIe),and[‘4C]formaldehyde(2 @Ci/@moIe) Cancer Institute, NIH, and by the John Phyffe Richardson Fund. 2 The abbreviations used are: CH3-H4folate, N'.methyltetrahydrofolate; were obtained from Amersham/Searle Corp. , Arlington AdoMet, S-adenosylmethionine; N,N'0-methylene-H4folate, N5,N'0@methyl@ Heights, Ill. [i4C]CHHfolatewasstored undenN2at —20°as enetetrahydrofolate; H4folate, tetrahydrofolate; FAD, flavin adenine dinucleo a 4.5 mM solution in 1 M mercaptoethanol at pH 7. 3',5'- tide; N5-formyl-H4folate, N5-formyltetrahydrofolate; FMN, riboflavin 5'-phos phate; N, N'°-methenyl-H4folate, N5,N' °-methenyltetrahydrofolate ; CLL, [3HJfoIic acid (22 @Ci/@mole)waspurchased from Schwarz/ chronic lymphocytic leukemia; CML, chronic myelocytic leukemia. Ab Mann, Onangeburg, N. Y.; N5-formyl-H4folate, calcium Ieu breviatlons of cofactors are in accordance with standard usage in The covonin, was obtained from Lederle Laboratories, Pearl Journal of Biological Chemistry. Received August 2, 1976; accepted December 29, 1976. Riven, N. V.; tryptamine hydrochloride, N-methyltnyptamine, APRIL 1977 1125 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1977 American Association for Cancer Research. J. Thorndike and W. S. Beck f3-phenylethylamine, AdoMet, FAD, and folic acid were pro disrupted and centrifuged as described for blood leuko duced by Sigma Chemical Co., St. Louis, Mo. FMN, NADH, cytes. and NADPH were obtained from Calbiochem, La Jolla, - Assay of Formaldehyde ProductIon from CH3-H4folate. Calif.; NAD and NADP were from Boehringer/Mannheim, Cell extracts were incubated with [i4C]CH3@H4foIatein the Mannheim, West Germany; cyanocobalamin was from presence of a saturating concentration of tryptammne. Dun Schwarz/Mann. Silica gel and cellulose thin-layer Chroma ing this incubation, enzymatically produced HCHO was gram sheets were purchased from Eastman Kodak Co., converted to the corresponding carboline, which was ex Rochester, N. V. tracted in toluene:isoamyl alcohol (pH 10) (14). Standard Methylcobalamin and propylcobalamin were synthesized incubation mixtures contained (in a total volume of 0.25 ml): by reduction of cyaflocobalamin with sodium borohydride, [14C]CH3-H4folate,9 nmoles; tryptamine, 5 @moles;FAD,0.5 followed by alkylation with methyl iodide and propyl bro @mole;potassium phosphate (pH 6.5), 25 @moles;andcell mide, respectively (32). Dihydrofolate and H4folate were extract,0to0.5mg protein.Afterincubationfor30mm at37° prepared by reduction of folic acid with sodium hydrosulfite in the dark, 0.5 ml of 0.5 M sodium borate (pH 10) was (11) or sodium borohydride (40), respectively. N5,N10-meth added; tryptoline was extracted with 3.5 ml of tolu enyl-H4folate was prepared by boiling H4folate in 80% formic ene:isoamyl alcohol (97:3) (‘‘tolueneextract'‘and‘‘toluene acid:0.1 M mercaptoethanol for 5 mm (37) on by treat extractible―are used in subsequent discussion to refer to ment of N5-formyl-H4folate with HCI (33). N5,N'°-methenyl this extraction). After centnifugation for 5 mm at 400 x g, [3H]H4folate, prepared by reduction of [3H]folic acid with aliquots of the toluene extract were evaporated to dryness sodium borohydride (40) and boiling with formic acid (37), and taken up in 1 ml isoamyl alcohol. Radioactivity was was purified by chromatography on cellulose thin-layer assayed in Aquasol liquid scintillation fluid in a Beckman sheets in 1 N formic acid:0.2 M mercaptoethanol, followed LS-150 scintillation counter. Incubations lacking enzyme by elution with 0.1 M mercaptoethanol. Unlabeled N5,N'°- were used as controls. Enzyme activity was expressed as methenyl-H4folate (which gives a fluorescent spot at AF nmoles HCHO formed pen hr pen mg protein. 0.24) was used as reference standard. N5,N10-['4Cjmethyl Chromatographlc Characterization of Reaction Prod ene-H4folate was prepared from [14C]HCHO and H4folate ucts. Chromatognaphic methods differed depending on (18). CH3-[―C]H4folate was synthesized by reduction of whether substrates were [“C]CH3-H4folateon CH3-[2- [2-―C]folicacid with sodium borohydnide and methylation “C)H4folate.Whenthe substrate was [‘4C]CH3-H4folatein with unlabeled HCHO in the presence of borohydride standard incubation mixtures, aliquots of toluene extracts (8); samples were purified by chromatography on cellulose were applied to a silica gel thin-layer chromatography sheet thin-layer sheets in 0.1 M potassium phosphate:0.2 M men and developed in acetone:1 N ammonium hydroxide (10:3) captoethanol, eluted with 0.2 M mercaptoethanol, and (16). In a separate reference mixture, 0.05 ml of a 40 @M evaporated to a smaller volume under N2. [@C]CH3-H4folate solution of [14C]formaldehyde was mixed with 0.2 ml of 125 was used as reference standard. mM tryptamine and 0.5 ml of 0.5 M sodium borate (pH 10) PreparatIon of Lymphocytes and Granulocytes. Leuko and extracted with 3.5 ml of toluene:isoamyl alcohol (97:3). cytes were obtained from venous blood (10 to 60 ml) of Aliquots of this toluene extract were chromatographed on ostensibly normal subjects and patients with the following the same sheet. A reference sample of nonnadioactive N- various disorders: CLL, CML, unexplained monocytosis, methyltryptamine was also developed on the same sheet. and severe cobalamin deficiency (mean corpuscular vol Sheets were dried, examined under UV, cut into portions, ume, 117 cu @m;serumcobalamin, 20 pg/mI). Some of the and assayed for radioactivity in Aquasol liquid scintillation leukemic subjects were receiving prednisone and cyclo fluid. phosphamide (CLL) or busulfan (CML); none was receiving However, when the substrate was CH3-[2-'4C]H4folate,be folic acid.
Load more

Recommended publications
  • Methionine Synthase Supports Tumor Tetrahydrofolate Pools
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Methionine synthase supports tumor tetrahydrofolate pools Joshua Z. Wang1,2,#, Jonathan M. Ghergurovich1,3,#, Lifeng Yang1,2, and Joshua D. Rabinowitz1,2,* 1 Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, USA 2 Department of Chemistry, Princeton University, Princeton, New Jersey, USA 3 Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA # These authors contributed equally to this work. *Corresponding author: Joshua Rabinowitz Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Rd, Princeton, NJ 08544, USA Phone: (609) 258-8985; e-mail: [email protected] Conflict of Interest Disclosure: J.D.R. is a paid advisor and stockholder in Kadmon Pharmaceuticals, L.E.A.F. Pharmaceuticals, and Rafael Pharmaceuticals; a paid consultant of Pfizer; a founder, director, and stockholder of Farber Partners and Serien Therapeutics. JDR and JMG are inventors of patents in the area of folate metabolism held by Princeton University. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Mammalian cells require activated folates to generate nucleotides for growth and division. The most abundant circulating folate species is 5-methyl tetrahydrofolate (5-methyl- THF), which is used to synthesize methionine from homocysteine via the cobalamin-dependent enzyme methionine synthase (MTR).
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • One Carbon Metabolism and Its Clinical Significance
    One carbon metabolism and its clinical significance Dr. Kiran Meena Department of Biochemistry Class 5 : 10-10-2019 (8:00 to 9:00 AM ) Specific Learning Objectives Describe roles of folic acid, cobalamin and S-adenosylmethionine (SAM) in transfer of one carbon units between molecules, and apply their relevance to disease states Describe synthesis of S-adenosylmethionine and its role in methylation reactions Explain how a cobalamin deficiency leads to a secondary folate deficiency Introduction Human body cannot synthesize folic acid Its also called vitamin B9 give rise to tetrahydrofolate (THF), carry one carbon groups ex. Methyl group Intestines releases mostly N5-methy-THF into blood One-carbon (1C) metabolism, mediated by folate cofactor, supports biosynthesis of purines and pyrimidines, aa homeostasis (glycine, serine and methionine) Table 14.4: DM Vasudevan’ s Textbook of Biochemistry for Medical Students 6th edition Enzyme co-factors involved in aa catabolism Involves one of three co-factors: Biotin, Tetrahydrofolate (THF) and S- adenosylmethionine (SAM) These cofactors transfer one-carbon groups in different oxidation states: 1. Biotin transfers carbon in its most oxidized state CO2, it require for catabolism and utilization of branched chain aa • Biotin responsible for carbon dioxide transfer in several carboxylase enzymes Cont-- 2. Tetrahydrofolate (THF) transfers one-carbon groups in intermediate oxidation states and as methyl groups • Tetrahydrobiopterin (BH4, THB) is a cofactor of degradation of phenylalanine • Oxidised form of THF, folate is vitamin for mammals • It converted into THF by DHF reductase 3. S-adenosylmethionine (SAM) transfers methyl groups, most reduced state of carbon THF and SAM imp in aa and nucleotide metabolism SAM used in biosynthesis of creatine, phosphatidylcholine, plasmenylcholine and epinephrine, also methylated DNA, RNA and proteins Enzymes use cobalamin as a cofactor 1.
    [Show full text]
  • The Vitamin B12 Coenzyme
    THE VITAMIN B12 COENZYME D. DoLPHIN, A. W. JoHNSON, R. RoDRIGO and N. SHAW Department of Chemistry, University of Nottingham, U.K. INTRODUCTION In 19•58 Barker and his associatesl-3 recognized a new coenzyme which controlled the conversion of glutamate into ß-methylaspartate by Clostridium tetanomorpkim. The coenzyme was shown4 to be related to !f;-vitamin B12, i.e. contair ing an adenine nucleotide grouping in place of the 5,6-dimethyl­ benziminawle nucleotide of vitamin B12, although similar coenzymes con­ taining btnziminazole or 5,6-dimethylbenziminazole were produced by growing C. tetanomorphum in the presence of the a ppropriate base5. Other variations of the nucleotide base have been achieved using Propionibacterium arabinosum in the presence of other purines and benziminazoles6• The pres­ ence of;:he coenzymes in a wide variety of micro-organisms such as several species of Actinomycetes including Streptomyces olivaceus and S. griseus has been dem( mstrated by the glutamate isomerase assay7 or by isolation. I t appears thü Vitamin B12 and its analogues are always biosynthesized in the form of their coenzymes. Preliminary physical and chemical studies sug­ gested that in the 5,6-dimethylbenzirninazolyl cobamide coenzyme the cyanide gr )up of vitamin B12, cyanocobalamin, was replaced by an adenine nucleoside':, 5, 8 and the determination9 of the complete structure (I; R = 5'-de·)xyadenosyl) of the coenzyme by X-ray analysis revealed the existence c f an essentially covalent bond between the cobalt atom and the S'.. carbon üom of the additional 5'-deoxyadenosine group. The molecule Me CH 2• CO· NH2 In the vitamin 8 12 coenzyme R =5' - deoxyadenosyl = Me Me 539 D.
    [Show full text]
  • L-Carnitine, Mecobalamin and Folic Acid Tablets) TRINERVE-LC
    For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only (L-Carnitine, Mecobalamin and Folic acid Tablets) TRINERVE-LC 1. Name of the medicinal product Trinerve-LC Tablets 2. Qualitative and quantitative composition Each film- coated tablets contains L-Carnitine…………………….500 mg Mecobalamin……………….1500 mcg Folic acid IP…………………..1.5mg 3. Pharmaceutical form Film- coated tablets 4. Clinical particulars 4.1 Therapeutic indications Vitamin and micronutrient supplementation in the management of chronic disease. 4.2 Posology and method of administration For oral administration only. One tablet daily or as directed by physician. 4.3 Contraindications Hypersensitivity to any constituent of the product. 4.4 Special warnings and precautions for use L-Carnitine The safety and efficacy of oral L-Carnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral L-Carnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine. Mecobalamin Should be given with caution in patients suffering from folate deficiency. The following warnings and precautions suggested with parent form – vitamin B12 The treatment of vitamin B12 deficiency can unmask the symptoms of polycythemia vera. Megaloblastic anemia is sometimes corrected by treatment with vitamin B12. But this can have very serious side effects. Don’t attempt vitamin B12 therapy without close supervision by healthcare provider. Do not take vitamin B12 if Leber’s disease, a hereditary eye disease.
    [Show full text]
  • The Potential Protective Role of Vitamin K in Diabetic Neuropathy
    VITAMINS The potential protective role of vitamin K in diabetic neuropathy DILIP MEHTA Viridis Biopharma 6/10 Jogani Industrial Complex ew cases of diabetes are symptomatic pain relief (3-5). V. N. Purav Marg, Chunabhatti increasing worldwide at a rapid Mumbai 400022, India The etiopathology of peripheral pace, with the total number of neuropathy is poorly understood and many [email protected] people with diabetes was projected factors, including dietary deficiencies, may www.viridisbiopharma.com Nto rise from 171 million in 2000 to 366 million contribute to the clinical manifestation of the in 2030 – an increase of nearly 200 million in condition. Deficiency of vitamin B12 (also only three decades. There are more cases of known as cobalamin), which results in a lack diabetes in women and urban populations, of a related compound, methylcobalamin, is with diabetes in developing countries projected manifested by megaloblastic anemia, and to double in the coming years (1). has been associated with significant Based on reports from the Centers for neurological pathology, especially peripheral Disease Control and Prevention, type 2 neuropathy (6-8). Vitamin B12 is also diabetes dult onset diabetes affects associated with the onset of diabetic approximately 9.3% of the general neuropathy. In patients with diabetic population in the United States in contrast to neuropathy, vitamin B12 deficiency may be 25.9% among those 65 years or older (2). aggravated by the use of antidiabetic agents Diabetes mellitus accounts for 90% of the such as metformin (9-11). Even short-term cases of diabetes patients (3,4). treatment with metformin causes a decrease The prevalence of type 2 diabetes in serum cobalamin, folic acid and an increases with age, higher then 25 body increase in homocysteine, which leads to mass index and the presence of the disease peripheral neuropathy in patients with in family history.
    [Show full text]
  • Potential Benefits of Methylcobalamin: a Review
    Open Access Austin Journal of Pharmacology and Therapeutics Review Article Potential Benefits of Methylcobalamin: A Review Gupta JK* and Qureshi Shaiba Sana Department of Pharmacology, GLA University Mathura, Abstract India Methylcobalamin is an active form of vitamin B12 that helps in synthesis *Corresponding author: Jeetendra Kumar Gupta, of methionine and S-adenosylmethionine. It is required for integrity of myelin, Department of Pharmacology, Institute of Pharmaceutical neuronal function, proper red blood cell formation and DNA synthesis. The largest Research, GLA University Mathura, India group of vitamin B12 deficiency is found in typical vegetarians all over the world, which can be alleviated with its analogue Methylcobalamin. It is a beneficial Received: August 17, 2015; Accepted: September 30, drug to most of the common disorders like cardiovascular disorders, diabetes, 2015; Published: October 08, 2015 anemia, hyperhomocysteinemia and degenerative disorders. Methylcobalamin helps in the synthesis of neuronal lipids, regeneration of axonal nerves and has neuroprotective activity, which promote neurons to function in proper way and thus improves Alzheimer disease, Parkinsonism, Dementia and neuropathic syndromes. It is an approved treatment for peripheral neuropathy. Keywords: Mecobalamin; Neuropathy; Anemia; Nootropic; Dietary supplement Abbreviations essential for cell growth and replication. Sometimes the liver cannot convert cyanocobalamin into adequate amount of methylcobalamin SAMe: S-Adenosyl Methionine; ERK: Extracellular Signal- needed for proper neuronal functioning. Through enhanced Regulated Kinases; PKB: Protein Kinase B; B-globulin: Beta Globulin; methylation, it exerts its nerve cell protective effect and accelerates ENFD: Epidermal Nerve Fiber Density; DPN: Diabetic Peripheral its growth. A lot of energy is required for cyanocobalamin to remove Neuropathy; NSAIDs: Non Steroidal Anti Inflammatory Drugs; THF: its cyanide and replaces it with methyl group [3].
    [Show full text]
  • Vitamin and Mineral Requirements in Human Nutrition
    P000i-00xx 3/12/05 8:54 PM Page i Vitamin and mineral requirements in human nutrition Second edition VITPR 3/12/05 16:50 Page ii WHO Library Cataloguing-in-Publication Data Joint FAO/WHO Expert Consultation on Human Vitamin and Mineral Requirements (1998 : Bangkok, Thailand). Vitamin and mineral requirements in human nutrition : report of a joint FAO/WHO expert consultation, Bangkok, Thailand, 21–30 September 1998. 1.Vitamins — standards 2.Micronutrients — standards 3.Trace elements — standards 4.Deficiency diseases — diet therapy 5.Nutritional requirements I.Title. ISBN 92 4 154612 3 (LC/NLM Classification: QU 145) © World Health Organization and Food and Agriculture Organization of the United Nations 2004 All rights reserved. Publications of the World Health Organization can be obtained from Market- ing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permis- sion to reproduce or translate WHO publications — whether for sale or for noncommercial distri- bution — should be addressed to Publications, at the above address (fax: +41 22 791 4806; e-mail: [email protected]), or to Chief, Publishing and Multimedia Service, Information Division, Food and Agriculture Organization of the United Nations, 00100 Rome, Italy. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization and the Food and Agriculture Organization of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • The Efficacy and Safety of Intramuscular Injections Of
    Original Article Singapore Med J 2011; 52(12) : 868 The efficacy and safety of intramuscular injections of methylcobalamin in patients with chronic nonspecific low back pain: a randomised controlled trial Chiu C K, Low T H, Tey Y S, Singh V A, Shong H K ABSTRACT both singly or in combination with other forms Introduction:Chronic, nonspecific low back of treatment. pain is a difficult ailment to treat and poses an economic burden in terms of medical Keywords: methylcobalamin, nonspecific low expenses and productivity loss. The aim of back pain, vitamin B12 this study was to determine the efficacy and Singapore Med J 2011; 52(12): 868-873 safety of intramuscular metylcobalamin in the treatment of chronic nonspecific low back INTRODUCTION pain. Low back pain (LBP) affects a substantial proportion of the population. Almost every person will encounter an Methods: This was a double-blinded, episode of back pain at some point in one’s life. Back randomised, controlled experimental study. pain does not discriminate based on gender, age, race or 60 patients were assigned to either the culture. It disables the working adult from performing his methylcobalamin group or the placebo group. duties and paralyses the society due to the cost incurred The former received intramuscular injections in terms of treatment and productivity loss. In 1988, a of 500 mcg parenteral methylcobalamin in 1 survey was conducted in a semirural area in Malaysia. Department of ml solution three times a week for two weeks, Orthopaedic A total of 2,594 individuals from a multi-racial (Malay, Surgery, and the placebo group received 1 ml normal Chinese, Indian) community were interviewed.
    [Show full text]
  • Cyanocobalamin-A Case for Withdrawal
    686 Journal of the Royal Society of Medicine Volume 85 November 1992 Cyanocobalamin- a case for withdrawal: discussion paper A G Freeman MD FRCP Meadow Rise, 3 Lakeside, Swindon SN3 IQE Keywords: anaemia, pernicious; optic neuropathies; chronic cyanide intoxication; hydroxocobalamin; cyanocobalamin It seems evident that controversy still surrounds the reduced ability to detoxify the cyanide in the tobacco- treatment of pernicious anaemia and other vitamin smoke to which they are exposed'0. B12 deficiency disorders. The long quest for the 'anti- Patients with tobacco amblyopia who have normal pernicious anaemia factor' in the liver seemed to serum vitamin B12 levels need not continue therapy have ended in 1948 when pure cyanocobalamin was with intramuscular hydroxocobalamin once their isolated. This was found to be very active thera- visual acuity and visual fields have returned to peutically when given by intramuscular injection and normal providing they abstain from further smoking. was non-toxic in extremely high doses'. However, those patients who have low serum vitamin Lederle, in a recent commentary2, advocates that B12 levels or evidence of -defective vitamin B12 patients with pernicious anaemia should now be absorption will need to continue-indefinitely with treated with oral cyanocobalamin. He is not without hydroxocobalamin irrespective of their smoking support in that 40% of patients with pernicious habits as will all patients with pernicious anaemia anaemia in Sweden are being similarly treated3. and other vitamin B12 deficiency disorders who are He further states that such!- treatment is cheap at risk of developing- optic neuropathy if they and effective, produces clinical and haematological are smokers.
    [Show full text]
  • Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues
    Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-1927 Experimental Therapeutics, Molecular Targets, and Chemical Biology Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues Dong Wu,1 Yang Li,1 Gaojie Song,1 Chongyun Cheng,1 Rongguang Zhang,2 Andrzej Joachimiak,2 NeilShaw, 1 and Zhi-Jie Liu1 1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China and 2Structural Biology Center, Argonne National Laboratory, Argonne, Illinois Abstract of the one-carbon metabolic network, dihydrofolate reductase, 5,10-Methenyltetrahydrofolate synthetase (MTHFS) regulates which catalyzes the conversion of dihydrofolate to tetrahydrofolate. the flow of carbon through the one-carbon metabolic network, Similarly, colorectal and pancreatic cancers are routinely treated by which supplies essential components for the growth and administration of the pyrimidine analogue 5-fluorouracil (5-FU), proliferation of cells. Inhibition of MTHFS in human MCF-7 which inhibits thymidylate synthase (TS; ref. 6). TS converts breast cancer cells has been shown to arrest the growth of deoxyuridylate to deoxythymidylate using a carbon donated by cells. Absence of the three-dimensional structure of human 5,10-methylenetetrahydrofolate (Fig. 1). This conversion is essential MTHFS (hMTHFS) has hampered the rational design and for DNA synthesis (7). To increase the clinical efficiency of the optimization of drug candidates. Here, we report the treatment, 5-formyltetrahydrofolate is often coadministered along structures of native hMTHFS, a binary complex of hMTHFS with 5-FU. The beneficial effect of administering 5-formyltetrahy- with ADP, hMTHFS bound with the N5-iminium phosphate drofolate during the therapy with 5-FU is a consequence of the reaction intermediate, and an enzyme-product complex of 5,10-methenyltetrahydrofolate synthetase (MTHFS)–catalyzed hMTHFS.
    [Show full text]
  • Enbrace​​® ​HR DESCRIPTION​​: INGREDIENTS
    EnBrace® HR with DeltaFolate​ ™ ​ [1 NF Units] [15 mg DFE Folate] ​ ​ ANTI-ANEMIA PREPARATION as extrinsic/intrinsic factor concentrate plus folate. ​ Prescription Prenatal/Vitamin Drug For Therapeutic Use ​ ​ ​ Multi-phasic Capsules (30ct bottle) NDC 64661-650-30 ​ ​ ​ Rx Only [DRUG] ​ ​ ​ GLUTEN-FREE DESCRIPTION: EnBrace® HR is an​ orally administered prescription prenatal/vitamin drug for ​ ​ ​ ​ ​ ​ ​ ​ therapeutic use formulated for female macrocytic anemia patients that are in need of treatment, ​ and are under specific direction and monitoring of vitamin B12 and vitamin B9 status by a ​ ​ ​ ​ physician. EnBrace® HR is intended for women of childbearing age who are – or desire to ​ become, pregnant regardless of lactation status. EnBrace® HR may be prescribed for women at risk of depression as a result of folate or cobalamin deficiency - including folate-induced postpartum depression, or are at risk of folate-induced birth defects such as may be found with spina bifida and other neural tube defects (NTDs). INGREDIENTS: ​ Cobalamin intrinsic factor complex 1 NF Units* * ​ National​ Formulary Units (“NF UNITS”) equivalent to 50 mcg of active coenzyme cobalamin (as cobamamide concentrate with intrinsic factor) ALSO CONTAINS: 1 Folinic acid (B9-vitamer) 2.5 mg ​ ​ ​ ​ ​ + ​ 1 Control-release, citrated folic acid, DHF ​ (B9-Provitamin) 1 mg ​ ​ ​ ​ ​ 2 ​ Levomefolic acid (B9 & B12- cofactor) 5.23 mg 1 ​ ​ ​ ​ ​ ​ ​ ​ 6 mg DFE folate (vitamin B9) 2 ​ ​ 9​ mg DFE l-methylfolate magnesium (molar equivalent). FUNCTIONAL EXCIPIENTS: 13.6 mg FeGC as ferrous glycine cysteinate (1.5 mg 3 3,4 ​ elemental iron )​ [colorant], 25 mg ascorbates ​ (24 mg magnesium l-ascorbate, 1 mg ​ ​ ​ zinc l-ascorbate) [antioxidant], at least 23.33 mg phospholipid-omega3 complex5 ​ ​ ​ ​ [marine lipids], 500 mcg betaine (trimethylglycine) [acidifier], 1 mg magnesium ​ ​ ​ ​ l-threonate [stabilizer].
    [Show full text]